3 recruiting, 1 active not recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Pertuzumab Injection: new trials by email Literature Review of Pertuzumab Injection trials Research Report on Pertuzumab Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer SHR-A1811 for Injection, Docetaxel injection, Trastuzumab Injection - Early-stage or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 740 | 2025-10-23 | 2026-07-30 |
| Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery Trastuzumab emtansine, Pertuzumab Injection, Docetaxel - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer | Phase 2 | Recruiting | University of Chicago | 74 | 2025-03-18 | 2026-02-17 |
| DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer Disitamab Vedotin Injection, Pertuzumab Injection, Toripalimab - Breast Cancer | Phase 2 | Recruiting | RemeGen Co., Ltd. | 40 | 2023-11-28 | 2025-10-01 |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors DB-1303/BNT323, Pertuzumab Injection, Ritonavir - HER2-positive Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | DualityBio Inc. | 796 | 2022-01-31 | 2026-08-27 |
Breast Neoplasms (3) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Endometrial Neoplasms (1) · Gastrointestinal Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Stomach Neoplasms (1)
DualityBio Inc. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · RemeGen Co., Ltd. (1) · University of Chicago (1)
China (3) · Australia (1) · Nigeria (1) · Puerto Rico (1) · South Korea (1) · Taiwan (1) · United States (1)
Jianmin Fang, Ph.D (1) · Olufunmilayo Olopade (1)